Asthma News – April 25, 2023
Current asthma research, announcements and opportunities, collected and distributed by Michigan Department of Health & Human Services (MDHHS) Asthma Program Staff.
Sign up to receive weekly-ish news emails.
Check out the most recent
MDHHS asthma social media messages and share them with your networks.
This free web-based database was designed for researchers, scientists, health professionals, and research students to dig into the data to see how asthma prevalence on the national, state, and local levels can lead to disparities and impact the social determinants of health.
Teva Pharmaceutical Industries Ltd. plans to discontinue all its Digihaler® products sold in the U.S. on June 1. This includes: ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler. Both ProAir and AirDuo are available in Teva’s Respiclick products – the same medicine formulations without the digital component. Teva does not offer the ArmonAir formulation in a branded alternative or generic.
American Lung Association (ALA): Asthma Basics Workshops ~ May 7 and 15
The ALA's Asthma Basics program is now being offered as a live, virtual workshop. The program is ideal for frontline healthcare professionals, such as school nurses or community health workers, as well as individuals with asthma, parents of children with asthma, and co-workers, friends and family who want to learn more about asthma. Register:
The most common and most severe comorbidity of adult asthma in this study was chronic obstructive pulmonary disease. Other common comorbidities of adult asthma include acute rhinosinusitis, chronic rhinosinusitis with nasal polyps, atopic dermatitis, allergic rhinitis, dysfunctional breathing, diabetes, pneumonia, sleep apnoea and gastro-oesophageal reflux disease.
Mepolizumab significantly reduced asthma exacerbations and oral corticosteroid use in patients with allergic and non-allergic asthma, suggesting that mepolizumab provides real-world benefit in severe asthma irrespective of whether a patient has an allergic phenotype.
In some asthmatic patients with acute exacerbations who do not suppress eosinophils after a course of OCS, there is a paradoxical decrease in plasma microRNA-1 level and increase in thymic stromal lymphopoietin level versus in steroid responders, which may result in slower clinical recovery.